Thursday 16 October, 2025
Introduction: The main purpose of this study was to determine the pharmacokinetic (PK) models of CPT11 and its 4 main…
Read moreposter
Population pharmacokinetics of nalbuphine in neonates
Thursday 16 October, 2025
Nalbuphine is an agonist-antagonist opioid analgesic agent administered intravenuously in critically ill neonates undergoing invasive procedures. Differences in the maturation…
Read morePopulation Pharmacokinetic/Pharmacodynamic modelling of Ovidrel in HIV-related male hypogonadotropic hypogonadism
Thursday 16 October, 2025
Background. Hypogonadism due to hypothalamic, pituitary or testicular failure, may be observed in patients with HIV infection Testosterone deficiency causes…
Read moreNominal versus actual significance levels for the statistical model in NONMEM
Thursday 16 October, 2025
Aim: The likelihood ratio (LR) test is commonly used as a tool for judging statistical significance of parameters included in…
Read moreThe population pharmacokinetics of Onercept in healthy subjects
Thursday 16 October, 2025
AIMS: To characterise the pharmacokinetics of Onercept (recombinant human Tumor Necrosis Factor Binding Protein), r-hTBP-1, a soluble glycoprotein corresponding to…
Read moreFurther developments of the Fisher information matrix for the evaluation of population pharmacokinetic designs
Thursday 16 October, 2025
We extended the population Fisher information matrix, which was proposed to evaluate and optimise population pharmacokinetic designs. The first proposed…
Read morePopulation Pharmacokinetic/Pharmacodynamic modelling of Antide in patients undergoing stimulation of multiple follicular development for assisted reproductive technology with recombinant human Follicle Stimulating Hormone
Thursday 16 October, 2025
Background. Iturelix (Antide) has been shown to be effective for postponing the mid-cycle Luteinising Hormone (LH) surge in healthy female….
Read moreBayesian Optimal Design for Pharmacokinetic/Pharmacodynamic Fixed Effect Models
Thursday 16 October, 2025
Design issues of pharmacokinetic/pharmacodynamic studies have regained interest in recent years with simulation techniques of clinical trial designs being the…
Read moreHot Glucose “Minimal Model” Analysis to Investigate the Pharmacodynamics of an Insulin Sensitiser in Early Drug Development
Thursday 16 October, 2025
To get an early indication on the efficacy of a new insulin sensitizer, “Minimal Model” analysis was applied to glucose…
Read morePopulation PK-PD Modelling of Angiotensin II Receptor Antagonists (A2RA) as a Pharmaceutical Class
Thursday 16 October, 2025
The aim of this work was to assess the PK-PD relationships for various A2RA using a common model. The original…
Read more